Cytosorbents (NASDAQ:CTSO) Given Buy Rating at D. Boral Capital

Cytosorbents (NASDAQ:CTSO)‘s stock had its “buy” rating restated by stock analysts at D. Boral Capital in a research note issued on Tuesday,Benzinga reports. They presently have a $10.00 target price on the medical research company’s stock.

Separately, StockNews.com assumed coverage on shares of Cytosorbents in a research report on Wednesday, March 26th. They issued a “hold” rating on the stock. Two analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Cytosorbents has a consensus rating of “Moderate Buy” and a consensus price target of $4.67.

Cytosorbents Price Performance

CTSO stock opened at $1.00 on Tuesday. Cytosorbents has a one year low of $0.70 and a one year high of $1.61. The stock has a market capitalization of $54.68 million, a P/E ratio of -2.78 and a beta of 0.78. The company has a 50 day moving average price of $1.07 and a two-hundred day moving average price of $1.05. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.58 and a current ratio of 1.97.

Cytosorbents (NASDAQ:CTSO) last released its earnings results on Monday, March 31st. The medical research company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.04. Cytosorbents had a negative return on equity of 118.54% and a negative net margin of 49.47%. The firm had revenue of $9.20 million during the quarter, compared to analyst estimates of $10.09 million. As a group, sell-side analysts expect that Cytosorbents will post -0.3 EPS for the current year.

Hedge Funds Weigh In On Cytosorbents

Large investors have recently modified their holdings of the company. Geode Capital Management LLC increased its position in Cytosorbents by 7.5% during the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after purchasing an additional 32,415 shares in the last quarter. Skylands Capital LLC raised its stake in shares of Cytosorbents by 1.0% in the 4th quarter. Skylands Capital LLC now owns 2,781,622 shares of the medical research company’s stock valued at $2,531,000 after acquiring an additional 26,195 shares during the period. Millennium Management LLC purchased a new position in shares of Cytosorbents in the 4th quarter valued at $30,000. Northern Trust Corp lifted its holdings in shares of Cytosorbents by 22.3% during the 4th quarter. Northern Trust Corp now owns 91,560 shares of the medical research company’s stock valued at $83,000 after acquiring an additional 16,701 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in Cytosorbents during the 4th quarter worth $99,000. 32.87% of the stock is currently owned by hedge funds and other institutional investors.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.